Stroke remains one of the leading causes of death, disability, increased economic burden and decreased quality of life around ...

Privately-held Italian pharma company Italfarmaco today revealed that the European Commission (EC) has granted conditional ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX) ...

Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and AI-powered discovery capabilities. The Company anticipates that upcoming ...

Investigators from Anthem Biosciences Ltd. have published preclinical characterization data on their histone deacetylase (HDAC) inhibitor PAT-1102 for the potential treatment of cancer.

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

MILAN, Italy I June 06, 2025 I Italfarmaco S.p.A. announced today that the European Commission (EC) has granted conditional marketing authorisation for ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.